GT Biopharma, Inc DEF 14A, filed Oct 13, 2026

About this DEF 14A

GT Biopharma, Inc filed this DEF 14A on October 13, 2026.

GT Biopharma will ask stockholders on November 11, 2026 to eliminate obsolete preferred-stock charter provisions, increase authorized common stock from 25,000,000 to 250,000,000, approve issuance of 19.99% or more of outstanding shares, and authorize meeting adjournment. AI summary